APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hidradenitis Suppurativa Treatment

Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.

The exact cause of hidradenitis suppurativa is unknown, but it occurs near hair follicles where there are sweat glands, usually around the groin, bottom, breasts and armpits.

There's no cure for HS, but treatments and lifestyle changes can bring some relief and cut down on flare-ups.

Selected research

Market Analysis & Forecast

Global Hidradenitis Suppurativa Treatment Market Analysis and Forecast 2026-2032

28 December 2025195 pages

Choose your research edition.

Industry ResearchHidradenitis Suppurativa Treatment Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Hidradenitis Suppurativa Treatment Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Hidradenitis Suppurativa Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hidradenitis Suppurativa Treatment Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Hidradenitis Suppurativa Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.

The exact cause of hidradenitis suppurativa is unknown, but it occurs near hair follicles where there are sweat glands, usually around the groin, bottom, breasts and armpits.

There's no cure for HS, but treatments and lifestyle changes can bring some relief and cut down on flare-ups.

Read the full market overview

The classification of Hidradenitis Suppurativa Treatment includes Medications, Surgery and others, and the proportion of Medications in 2019 is about 76%.

Hidradenitis Suppurativa Treatment is widely used in Hospital, Clinical and other field. The most proportion of Hidradenitis Suppurativa Treatment is Hospital, and the proportion in 2019 is 53.53%.

Europe is the largest consumption place with a consumption market share of 47.76% in 2019. Following Europe, Asia Pacific is the second largest consumption place with the consumption market share of 23.97%.

Market competition is intense. AbbVie, Merck, Pfizer, AstraZeneca, GlaxoSmithKline, etc. are the leaders of the industry.

Report Includes

This report presents an overview of global market for Hidradenitis Suppurativa Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hidradenitis Suppurativa Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Hidradenitis Suppurativa Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hidradenitis Suppurativa Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hidradenitis Suppurativa Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Hidradenitis Suppurativa Treatment revenue, projected growth trends, production technology, application and end-user industry.

Hidradenitis Suppurativa Treatment Segment by Company

AbbVie

Merck

Pfizer

AstraZeneca

GlaxoSmithKline

Perrigo

Sun Pharma

Almirall

Bausch Health

Johnson & Johnson

Hidradenitis Suppurativa Treatment Segment by Type

Medications

Surgery

Others

Hidradenitis Suppurativa Treatment Segment by Application

Hospitals

Clinics

Others

Hidradenitis Suppurativa Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hidradenitis Suppurativa Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hidradenitis Suppurativa Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hidradenitis Suppurativa Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Hidradenitis Suppurativa Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Hidradenitis Suppurativa Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hidradenitis Suppurativa Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hidradenitis Suppurativa Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Medications Major Player Table 3. Surgery Major Player Table 4. Others Major Player Table 5. Global Hidradenitis Suppurativa Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Player Table 7. Clinics Major Player Table 8. Others Major Player Table 9. Hidradenitis Suppurativa Treatment Industry Trends Table 10. Hidradenitis Suppurativa Treatment Industry Drivers Table 11. Hidradenitis Suppurativa Treatment Industry Opportunities and Challenges Table 12. Hidradenitis Suppurativa Treatment Industry Restraints Table 13. Global Hidradenitis Suppurativa Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Hidradenitis Suppurativa Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Hidradenitis Suppurativa Treatment Market Share by Region (2021-2026) Table 16. Global Hidradenitis Suppurativa Treatment Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Hidradenitis Suppurativa Treatment Market Share by Region (2027-2032) Table 18. Global Hidradenitis Suppurativa Treatment Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Hidradenitis Suppurativa Treatment Revenue Market Share by Players (2021-2026) Table 20. Global Hidradenitis Suppurativa Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Hidradenitis Suppurativa Treatment Key Players Headquarters & Area Served Table 22. Global Hidradenitis Suppurativa Treatment Players, Product Type & Application Table 23. Global Hidradenitis Suppurativa Treatment Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Hidradenitis Suppurativa Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Hidradenitis Suppurativa Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Hidradenitis Suppurativa Treatment Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Hidradenitis Suppurativa Treatment Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Hidradenitis Suppurativa Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Hidradenitis Suppurativa Treatment Revenue Market Share by Type (2027-2032) Table 31. Global Hidradenitis Suppurativa Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Hidradenitis Suppurativa Treatment Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Hidradenitis Suppurativa Treatment Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Hidradenitis Suppurativa Treatment Revenue Market Share by Application (2021-2026) Table 35. Global Hidradenitis Suppurativa Treatment Revenue Market Share by Application (2027-2032) Table 36. AbbVie Company Information Table 37. AbbVie Business Overview Table 38. AbbVie Hidradenitis Suppurativa Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. AbbVie Hidradenitis Suppurativa Treatment Product Portfolio Table 40. AbbVie Recent Development Table 41. Merck Company Information Table 42. Merck Business Overview Table 43. Merck Hidradenitis Suppurativa Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Merck Hidradenitis Suppurativa Treatment Product Portfolio Table 45. Merck Recent Development Table 46. Pfizer Company Information Table 47. Pfizer Business Overview Table 48. Pfizer Hidradenitis Suppurativa Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Pfizer Hidradenitis Suppurativa Treatment Product Portfolio Table 50. Pfizer Recent Development Table 51. AstraZeneca Company Information Table 52. AstraZeneca Business Overview Table 53. AstraZeneca Hidradenitis Suppurativa Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. AstraZeneca Hidradenitis Suppurativa Treatment Product Portfolio Table 55. AstraZeneca Recent Development Table 56. GlaxoSmithKline Company Information Table 57. GlaxoSmithKline Business Overview Table 58. GlaxoSmithKline Hidradenitis Suppurativa Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. GlaxoSmithKline Hidradenitis Suppurativa Treatment Product Portfolio Table 60. GlaxoSmithKline Recent Development Table 61. Perrigo Company Information Table 62. Perrigo Business Overview Table 63. Perrigo Hidradenitis Suppurativa Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Perrigo Hidradenitis Suppurativa Treatment Product Portfolio Table 65. Perrigo Recent Development Table 66. Sun Pharma Company Information Table 67. Sun Pharma Business Overview Table 68. Sun Pharma Hidradenitis Suppurativa Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Sun Pharma Hidradenitis Suppurativa Treatment Product Portfolio Table 70. Sun Pharma Recent Development Table 71. Almirall Company Information Table 72. Almirall Business Overview Table 73. Almirall Hidradenitis Suppurativa Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Almirall Hidradenitis Suppurativa Treatment Product Portfolio Table 75. Almirall Recent Development Table 76. Bausch Health Company Information Table 77. Bausch Health Business Overview Table 78. Bausch Health Hidradenitis Suppurativa Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Bausch Health Hidradenitis Suppurativa Treatment Product Portfolio Table 80. Bausch Health Recent Development Table 81. Johnson & Johnson Company Information Table 82. Johnson & Johnson Business Overview Table 83. Johnson & Johnson Hidradenitis Suppurativa Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Johnson & Johnson Hidradenitis Suppurativa Treatment Product Portfolio Table 85. Johnson & Johnson Recent Development Table 86. North America Hidradenitis Suppurativa Treatment Revenue by Type (2021-2026) & (US$ Million) Table 87. North America Hidradenitis Suppurativa Treatment Revenue by Type (2027-2032) & (US$ Million) Table 88. North America Hidradenitis Suppurativa Treatment Revenue by Application (2021-2026) & (US$ Million) Table 89. North America Hidradenitis Suppurativa Treatment Revenue by Application (2027-2032) & (US$ Million) Table 90. North America Hidradenitis Suppurativa Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. North America Hidradenitis Suppurativa Treatment Revenue by Country (2021-2026) & (US$ Million) Table 92. North America Hidradenitis Suppurativa Treatment Revenue by Country (US$ Million) & (2027-2032) Table 93. Europe Hidradenitis Suppurativa Treatment Revenue by Type (2021-2026) & (US$ Million) Table 94. Europe Hidradenitis Suppurativa Treatment Revenue by Type (2027-2032) & (US$ Million) Table 95. Europe Hidradenitis Suppurativa Treatment Revenue by Application (2021-2026) & (US$ Million) Table 96. Europe Hidradenitis Suppurativa Treatment Revenue by Application (2027-2032) & (US$ Million) Table 97. Europe Hidradenitis Suppurativa Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Europe Hidradenitis Suppurativa Treatment Revenue by Country (2021-2026) & (US$ Million) Table 99. Europe Hidradenitis Suppurativa Treatment Revenue by Country (US$ Million) & (2027-2032) Table 100. China Hidradenitis Suppurativa Treatment Revenue by Type (2021-2026) & (US$ Million) Table 101. China Hidradenitis Suppurativa Treatment Revenue by Type (2027-2032) & (US$ Million) Table 102. China Hidradenitis Suppurativa Treatment Revenue by Application (2021-2026) & (US$ Million) Table 103. China Hidradenitis Suppurativa Treatment Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia Hidradenitis Suppurativa Treatment Revenue by Type (2021-2026) & (US$ Million) Table 105. Asia Hidradenitis Suppurativa Treatment Revenue by Type (2027-2032) & (US$ Million) Table 106. Asia Hidradenitis Suppurativa Treatment Revenue by Application (2021-2026) & (US$ Million) Table 107. Asia Hidradenitis Suppurativa Treatment Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia Hidradenitis Suppurativa Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Asia Hidradenitis Suppurativa Treatment Revenue by Region (US$ Million) & (2021-2026) Table 110. Asia Hidradenitis Suppurativa Treatment Revenue by Region (US$ Million) & (2027-2032) Table 111. SAMEA Hidradenitis Suppurativa Treatment Revenue by Type (2021-2026) & (US$ Million) Table 112. SAMEA Hidradenitis Suppurativa Treatment Revenue by Type (2027-2032) & (US$ Million) Table 113. SAMEA Hidradenitis Suppurativa Treatment Revenue by Application (2021-2026) & (US$ Million) Table 114. SAMEA Hidradenitis Suppurativa Treatment Revenue by Application (2027-2032) & (US$ Million) Table 115. SAMEA Hidradenitis Suppurativa Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. SAMEA Hidradenitis Suppurativa Treatment Revenue by Country (2021-2026) & (US$ Million) Table 117. SAMEA Hidradenitis Suppurativa Treatment Revenue by Country (US$ Million) & (2027-2032) Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Hidradenitis Suppurativa Treatment Image Figure 2. Global Hidradenitis Suppurativa Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hidradenitis Suppurativa Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Medications Image Figure 5. Surgery Image Figure 6. Others Image Figure 7. Global Hidradenitis Suppurativa Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Hidradenitis Suppurativa Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Others Image Figure 12. Global Hidradenitis Suppurativa Treatment Market Size (US$ Million) & (2021-2032) Figure 13. Global Hidradenitis Suppurativa Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Hidradenitis Suppurativa Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Hidradenitis Suppurativa Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Hidradenitis Suppurativa Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Hidradenitis Suppurativa Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Hidradenitis Suppurativa Treatment Revenue Market Share by Type (2021-2032) Figure 20. Global Hidradenitis Suppurativa Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Hidradenitis Suppurativa Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Hidradenitis Suppurativa Treatment Revenue Market Share by Application (2021-2032) Figure 23. North America Hidradenitis Suppurativa Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Hidradenitis Suppurativa Treatment Revenue Share by Type (2021-2032) Figure 25. North America Hidradenitis Suppurativa Treatment Revenue Share by Application (2021-2032) Figure 26. North America Hidradenitis Suppurativa Treatment Revenue Share by Country (2021-2032) Figure 27. United States Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Hidradenitis Suppurativa Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Hidradenitis Suppurativa Treatment Revenue Share by Type (2021-2032) Figure 32. Europe Hidradenitis Suppurativa Treatment Revenue Share by Application (2021-2032) Figure 33. Europe Hidradenitis Suppurativa Treatment Revenue Share by Country (2021-2032) Figure 34. Germany Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Hidradenitis Suppurativa Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Hidradenitis Suppurativa Treatment Revenue Share by Type (2021-2032) Figure 44. China Hidradenitis Suppurativa Treatment Revenue Share by Application (2021-2032) Figure 45. Asia Hidradenitis Suppurativa Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Hidradenitis Suppurativa Treatment Revenue Share by Type (2021-2032) Figure 47. Asia Hidradenitis Suppurativa Treatment Revenue Share by Application (2021-2032) Figure 48. Asia Hidradenitis Suppurativa Treatment Revenue Share by Region (2021-2032) Figure 49. Japan Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Hidradenitis Suppurativa Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Hidradenitis Suppurativa Treatment Revenue Share by Type (2021-2032) Figure 57. SAMEA Hidradenitis Suppurativa Treatment Revenue Share by Application (2021-2032) Figure 58. SAMEA Hidradenitis Suppurativa Treatment Revenue Share by Country (2021-2032) Figure 59. Brazil Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Hidradenitis Suppurativa Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Medications
  • Surgery
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • AbbVie
  • Merck
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Perrigo
  • Sun Pharma
  • Almirall
  • Bausch Health
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hidradenitis Suppurativa Treatment Market by Type
  3. 1.2.1 Global Hidradenitis Suppurativa Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Medications
  5. 1.2.3 Surgery
  6. 1.2.4 Others
  7. 1.3 Hidradenitis Suppurativa Treatment Market by Application
  8. 1.3.1 Global Hidradenitis Suppurativa Treatment Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Hidradenitis Suppurativa Treatment Market Dynamics
  1. 2.1 Hidradenitis Suppurativa Treatment Industry Trends
  2. 2.2 Hidradenitis Suppurativa Treatment Industry Drivers
  3. 2.3 Hidradenitis Suppurativa Treatment Industry Opportunities and Challenges
  4. 2.4 Hidradenitis Suppurativa Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Hidradenitis Suppurativa Treatment Market Perspective (2021-2032)
  2. 3.2 Global Hidradenitis Suppurativa Treatment Growth Trends by Region
  3. 3.2.1 Global Hidradenitis Suppurativa Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hidradenitis Suppurativa Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Hidradenitis Suppurativa Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Hidradenitis Suppurativa Treatment Revenue by Players
  2. 4.1.1 Global Hidradenitis Suppurativa Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Hidradenitis Suppurativa Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Hidradenitis Suppurativa Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hidradenitis Suppurativa Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Hidradenitis Suppurativa Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Hidradenitis Suppurativa Treatment Players, Product Type & Application
  8. 4.5 Global Hidradenitis Suppurativa Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Hidradenitis Suppurativa Treatment Market CR5 and HHI
  11. 4.6.3 2025 Hidradenitis Suppurativa Treatment Tier 1, Tier 2, and Tier 3
5 Hidradenitis Suppurativa Treatment Market Size by Type
  1. 5.1 Global Hidradenitis Suppurativa Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Hidradenitis Suppurativa Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Hidradenitis Suppurativa Treatment Revenue Market Share by Type (2021-2032)
6 Hidradenitis Suppurativa Treatment Market Size by Application
  1. 6.1 Global Hidradenitis Suppurativa Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Hidradenitis Suppurativa Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Hidradenitis Suppurativa Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AbbVie
  2. 7.1.1 AbbVie Company Information
  3. 7.1.2 AbbVie Business Overview
  4. 7.1.3 AbbVie Hidradenitis Suppurativa Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AbbVie Hidradenitis Suppurativa Treatment Product Portfolio
  6. 7.1.5 AbbVie Recent Developments
  7. 7.2 Merck
  8. 7.2.1 Merck Company Information
  9. 7.2.2 Merck Business Overview
  10. 7.2.3 Merck Hidradenitis Suppurativa Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck Hidradenitis Suppurativa Treatment Product Portfolio
  12. 7.2.5 Merck Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Hidradenitis Suppurativa Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Hidradenitis Suppurativa Treatment Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 AstraZeneca
  20. 7.4.1 AstraZeneca Company Information
  21. 7.4.2 AstraZeneca Business Overview
  22. 7.4.3 AstraZeneca Hidradenitis Suppurativa Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca Hidradenitis Suppurativa Treatment Product Portfolio
  24. 7.4.5 AstraZeneca Recent Developments
  25. 7.5 GlaxoSmithKline
  26. 7.5.1 GlaxoSmithKline Company Information
  27. 7.5.2 GlaxoSmithKline Business Overview
  28. 7.5.3 GlaxoSmithKline Hidradenitis Suppurativa Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline Hidradenitis Suppurativa Treatment Product Portfolio
  30. 7.5.5 GlaxoSmithKline Recent Developments
  31. 7.6 Perrigo
  32. 7.6.1 Perrigo Company Information
  33. 7.6.2 Perrigo Business Overview
  34. 7.6.3 Perrigo Hidradenitis Suppurativa Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Perrigo Hidradenitis Suppurativa Treatment Product Portfolio
  36. 7.6.5 Perrigo Recent Developments
  37. 7.7 Sun Pharma
  38. 7.7.1 Sun Pharma Company Information
  39. 7.7.2 Sun Pharma Business Overview
  40. 7.7.3 Sun Pharma Hidradenitis Suppurativa Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Sun Pharma Hidradenitis Suppurativa Treatment Product Portfolio
  42. 7.7.5 Sun Pharma Recent Developments
  43. 7.8 Almirall
  44. 7.8.1 Almirall Company Information
  45. 7.8.2 Almirall Business Overview
  46. 7.8.3 Almirall Hidradenitis Suppurativa Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Almirall Hidradenitis Suppurativa Treatment Product Portfolio
  48. 7.8.5 Almirall Recent Developments
  49. 7.9 Bausch Health
  50. 7.9.1 Bausch Health Company Information
  51. 7.9.2 Bausch Health Business Overview
  52. 7.9.3 Bausch Health Hidradenitis Suppurativa Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bausch Health Hidradenitis Suppurativa Treatment Product Portfolio
  54. 7.9.5 Bausch Health Recent Developments
  55. 7.10 Johnson & Johnson
  56. 7.10.1 Johnson & Johnson Company Information
  57. 7.10.2 Johnson & Johnson Business Overview
  58. 7.10.3 Johnson & Johnson Hidradenitis Suppurativa Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Johnson & Johnson Hidradenitis Suppurativa Treatment Product Portfolio
  60. 7.10.5 Johnson & Johnson Recent Developments
8 North America
  1. 8.1 North America Hidradenitis Suppurativa Treatment Revenue (2021-2032)
  2. 8.2 North America Hidradenitis Suppurativa Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Hidradenitis Suppurativa Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Hidradenitis Suppurativa Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Hidradenitis Suppurativa Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Hidradenitis Suppurativa Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Hidradenitis Suppurativa Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Hidradenitis Suppurativa Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Hidradenitis Suppurativa Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Hidradenitis Suppurativa Treatment Revenue by Country
  11. 8.6.1 North America Hidradenitis Suppurativa Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Hidradenitis Suppurativa Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Hidradenitis Suppurativa Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Hidradenitis Suppurativa Treatment Revenue (2021-2032)
  2. 9.2 Europe Hidradenitis Suppurativa Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Hidradenitis Suppurativa Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Hidradenitis Suppurativa Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Hidradenitis Suppurativa Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Hidradenitis Suppurativa Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Hidradenitis Suppurativa Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Hidradenitis Suppurativa Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Hidradenitis Suppurativa Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Hidradenitis Suppurativa Treatment Revenue by Country
  11. 9.6.1 Europe Hidradenitis Suppurativa Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Hidradenitis Suppurativa Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Hidradenitis Suppurativa Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Hidradenitis Suppurativa Treatment Revenue (2021-2032)
  2. 10.2 China Hidradenitis Suppurativa Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Hidradenitis Suppurativa Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Hidradenitis Suppurativa Treatment Revenue by Type (2027-2032)
  5. 10.3 China Hidradenitis Suppurativa Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Hidradenitis Suppurativa Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Hidradenitis Suppurativa Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Hidradenitis Suppurativa Treatment Revenue by Application (2027-2032)
  9. 10.5 China Hidradenitis Suppurativa Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hidradenitis Suppurativa Treatment Revenue (2021-2032)
  2. 11.2 Asia Hidradenitis Suppurativa Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Hidradenitis Suppurativa Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Hidradenitis Suppurativa Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Hidradenitis Suppurativa Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Hidradenitis Suppurativa Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Hidradenitis Suppurativa Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Hidradenitis Suppurativa Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Hidradenitis Suppurativa Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Hidradenitis Suppurativa Treatment Revenue by Country
  11. 11.6.1 Asia Hidradenitis Suppurativa Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Hidradenitis Suppurativa Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Hidradenitis Suppurativa Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hidradenitis Suppurativa Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Hidradenitis Suppurativa Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Hidradenitis Suppurativa Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Hidradenitis Suppurativa Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Hidradenitis Suppurativa Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Hidradenitis Suppurativa Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Hidradenitis Suppurativa Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Hidradenitis Suppurativa Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Hidradenitis Suppurativa Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Hidradenitis Suppurativa Treatment Revenue by Country
  11. 12.6.1 SAMEA Hidradenitis Suppurativa Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Hidradenitis Suppurativa Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Hidradenitis Suppurativa Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst